Ionis Pharmaceuticals Inc (IONS)

06:54 AM

Wolfe Research reiterates Ionis Pharmaceuticals stock rating ahead of rival data - Investing.com

06:54 AM

May 25, 2026

Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts - inkl

May 25, 2026

May 25, 2026

Ionis Pharmaceuticals (IONS) Valuation Check After Biogen Releases Phase 2 CELIA Alzheimer’s Study Results - Sahm

May 25, 2026

May 25, 2026

Ionis Pharmaceuticals, Inc. (IONS): Investor Outlook Highlights 33.56% Potential Upside - DirectorsTalk Interviews

May 25, 2026

May 24, 2026

Understanding Momentum Shifts in (IONS) - Stock Traders Daily

May 24, 2026

May 24, 2026

IONS Q1 earnings & sales beat, stock rises on raised '26 view - MSN

May 24, 2026

May 23, 2026

Ionis Pharmaceuticals’ SWOT analysis: stock gains momentum on FDA approval - Investing.com Nigeria

May 23, 2026

May 22, 2026

Ionis, Alnylam, BioMarin up as Citi starts at buy on catalyst and growth outlook - MSN

May 22, 2026

May 22, 2026

IONS News | IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - ChartMill

May 22, 2026

May 21, 2026

IONS Stock Price, Quote & Chart | IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - ChartMill

May 21, 2026

May 20, 2026

Ionis Pharmaceuticals Inc : Citigroup Initiat - Moomoo

May 20, 2026

May 20, 2026

Ionis Rises As Diranersen Phase 2 Spurs Biogen Registrational Plans - simplywall.st

May 20, 2026

May 19, 2026

IONS Initiated Coverage by Citigroup -- Price Target Set at $115 - GuruFocus

May 19, 2026

May 19, 2026

Citi Initiates Coverage on Biotech Stocks: Ionis (IONS), Alnylam (ALNY), BioMarin (BMRN) - GuruFocus

May 19, 2026

May 19, 2026

Ionis Pharmaceuticals (IONS) Receives Bullish Target from Citi A - GuruFocus

May 19, 2026

May 19, 2026

J.P. Morgan Initiates Ionis Pharmaceuticals(IONS.US) With Buy Rating, Announces Target Price $115 - Moomoo

May 19, 2026

May 19, 2026

Ionis, Alnylam, BioMarin are new Buys at Citi (ALNY:NASDAQ) - Seeking Alpha

May 19, 2026

May 19, 2026

Ionis Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus

May 19, 2026

May 18, 2026

Ionis Pharmaceuticals touts $3B TRYNGOLZA opportunity, pipeline readouts at conference - MSN

May 18, 2026

May 18, 2026

Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment - GlobeNewswire Inc.

May 18, 2026

May 18, 2026

Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference - MarketBeat

May 18, 2026

May 18, 2026

Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Biotech Powerhouse with 35.77% Upside Potential - DirectorsTalk Interviews

May 18, 2026

May 17, 2026

Biogen posts mid-stage trial data for Alzheimer’s candidate developed with Ionis - MSN

May 17, 2026

May 17, 2026

Ionis Pharmaceuticals repriced drug ahead of key FDA decision, signals push into larger market - MSN

May 17, 2026

May 15, 2026

Insider Sell: Brett Monia Sells Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus

May 15, 2026

May 15, 2026

Ionis Pharmaceuticals CEO Brett P. Monia sells $356,012 in shares By Investing.com - Investing.com South Africa

May 15, 2026

May 15, 2026

Ionis Pharmaceuticals CEO Brett P. Monia sells $356,012 in shares - Investing.com

May 15, 2026

May 15, 2026

Ionis (NASDAQ: IONS) CEO sells 4,536 shares after option exercise - Stock Titan

May 15, 2026

May 15, 2026

A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $105 to $115 - Moomoo

May 15, 2026

May 15, 2026

CCORF Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $110 - Moomoo

May 15, 2026

May 15, 2026

T. Rowe Price holds 6.16M IONS shares (NYSE: IONS) — 3.7% stake - Stock Titan

May 15, 2026

May 15, 2026

Needham Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $105 - Moomoo

May 15, 2026

May 15, 2026

Ionis validates ABL Bio’s Grabody-B to deliver RNA drugs to brainCHOSUNBIZ - Chosunbiz

May 15, 2026

May 15, 2026

Ionis Pharmaceuticals, Inc.Common Stock (NQ: IONS - FinancialContent

May 15, 2026

May 14, 2026

Biogen has seen enough — despite no dose response — to advance tau-directed therapy - FirstWord Pharma

May 14, 2026

May 14, 2026

Capital World Investors holds 12.8% of Ionis (NASDAQ: IONS) - Stock Titan

May 14, 2026

May 14, 2026

Biogen AD drug shows tau, cognition benefit, despite trial miss - BioWorld News

May 14, 2026

May 14, 2026

Number of shareholders of Ionis Pharmaceuticals, Inc. – NASDAQ:IONS - TradingView

May 14, 2026

May 14, 2026

Biogen plans registrational study for Alzheimer’s drug diranersen - Investing.com UK

May 14, 2026

May 14, 2026

Ionis partner Biogen announces topline results from phase 2 Celia study of diranersen - marketscreener.com

May 14, 2026

May 14, 2026

Biogen plans registrational study for Alzheimer’s drug diranersen By Investing.com - Investing.com Canada

May 14, 2026

May 14, 2026

Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease - ChartMill

May 14, 2026

May 14, 2026

Pinnacle Associates Ltd. Reduces Stake in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

May 14, 2026

May 14, 2026

A Look At Ionis Pharmaceuticals (IONS) Valuation After Recent Share Price Moves - Yahoo Finance

May 14, 2026

May 13, 2026

Ionis gets FDA breakthrough therapy status for zilganersen - MSN

May 13, 2026

May 13, 2026

Avoiding Lag: Real-Time Signals in (IONS) Movement - Stock Traders Daily

May 13, 2026